natgillin/translations-raw huggingface dataset:
4 weeks after the completion of primary course for Leptospira components.
4 tjedna nakon osnovnog cijepljenja (primovakcinacija) za Leptospire.
4 weeks and is still unrelated to leukaemia, stop imatinib until ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l, then resume treatment at 300 mg.
Ako citopenija potraje 4 tjedna i još uvijek nije povezana s leukemijom, prekinuti primjenu imatiniba sve dok ABN ne bude 1 x 109/l i trombociti 20 x 109/l, nakon toga nastaviti liječenje u dozi od 300 mg.
4 weeks for women with childbearing potential
4 tjedna za žene u reproduktivnoj dobi
4 x 0.25 mL injections, or
4 x 0,25 mL injekcija, ili
4 x 1 orodispersible tablets
4 x 1 raspadljive tablete za usta
4 x 1 single-
4 x 1 jednodozni
4 x 1 tablets (unit
4 x 1 tablete (s jediničnim dozama)
4 x 1 tablets (unit dose)
4 x 1 tablete (jedinična doza)
4 x 1 tablets (unit dose)
4 x 1 tablete (jedinične doze)
4 x 10 ml vials
4 x 10 ml bočice
4 x 125 doses
4 x 125 doza
4 x 200 mg tabletsb
4 x 200 mg tableteb
4 x 200 mga
4 x 200 mg a
4 x 320 mg / 40 mg tablets
4 x 320 mg / 40 mg tablete
4 x 4 ml vials
4 x 4 ml bočice
4 x 4,000
4 x 4.000
4 x 5 ml vials 10 x 5 ml vials
4 bočice od 5 ml 10 bočica od 5 ml
4 x 50 doses
4 x 50 doza
4 years
godine
4 years (2C – 8C)
4 godine (2C – 8C).
4 years.
godine.
4 – 10 cm (1.6 – 4 in)
4 – 10 cm
4% (13/299)
Ciroza
4) in patients with narcolepsy with cataplexy except for trial 2 where cataplexy was not required for enrolment Concomitant stimulant use was permitted in all trials (except for the active-treatment phase of Trial 2); antidepressants were withdrawn prior to active treatment in all trials with the exception of Trial 2.
Istodobna primjena stimulansa bila je dozvoljena u svim ispitivanjima (osim u aktivnoj fazi liječenja u Ispitivanju 2); u svim ispitivanjima je prije početka aktivnog liječenja prekinuta primjena svih antidepresiva osim u Ispitivanju 2.
4) or considered
do 4) ili one koje se
4, 50.016 Zaragoza, Spain TEVA UK Ltd, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
4, 50.016 Zaragoza, Španjolska TEVA UK Ltd, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, Ujedinjeno Kraljevstvo
4, Chemin du Calquet 31057 Toulouse Cedex France
4, Chemin du Calquet 31057 Toulouse Cedex Francuska
4, light peach opaque cap and light peach opaque body, hard-shell gelatin capsule filled with white to off-white powder.
4 sa svjetloružičastom neprozirnom kapicom i svjetloružičastim neprozirnim tijelom napunjena bjeličastim prahom.
4, light peach opaque cap and white opaque body, hard-shell gelatin capsule filled with white to off-white powder.
4 sa svjetloružičastom neprozirnom kapicom i bijelim neprozirnim tijelom napunjena bjeličastim prahom.
4, Poligono Industrial Malpica, 50016 Zaragoza Spain
4, Poligono Industrial Malpica, 50016 Zaragoza Španjolska
4,000 (number of doses per ampoule is presented on the colour coded clip attached to each cane containing the ampoule)
4000 (broj doza po ampuli je navedena na obojanoj oznaci priloženoj na svakoj kutiji koja sadrži ampule
4,000 doses
4.000 doza
4,000 doses
4000 doza
4,000 IU/0.4 ml
4000 IU/0,4 ml
4,000 IU/10 ml
4000 IU/10 ml
4,000 – 6,000 IU
4000-6000 IU
4,800 units*
4800 jedinica
4,800 units*,
4800 jedinica*,
4,832 patients with an acute symptomatic PE
4832 bolesnika s akutnim simptomatskom plućnom embolijom
4,832 patients with an acute symptomatic PE
4832 bolesnika s akutnom simptomatskom plućnom embolijom
4- 6 times per day in small children).
4-6 puta dnevno u male djece).
4-5 hours.
4-5 sati.
4-week treatment initiation pack
Četverotjedno pakiranje za početak terapije
4-week treatment initiation pack containing: 11 x 0.5 mg film-coated tablets and
Četverotjedno pakiranje za početak terapije koje sadrži: 11 x 0,5 mg filmom obloženih tableta i
4. p-value <0.0001.
4. p-vrijednost < 0,0001.
4.) Remove ITLC strip and cut in half at the 3.5 cm cut line.
4.) Izvadite trakicu za ITLC pa je prerežite na pola po reznoj crti od 3,5 cm.
4.0 mg zoledronic acid
4,0 mg zoledronatne kiseline
4.0 mL of concentrate solution should be injected into a 500 mL bag /bottle of irrigation solution.
4,0 mL otopine koncentrata treba ubrizgati u vrećicu/bocu od 500 mL otopine irigata.
4.0 ml twice daily
4,0 ml dva puta dnevno
4.0%)a, b
(-6,2%; 4,0%)a, b
4.02 (2.94, 5.50)
4,02 (2,94; 5,50) p<0,0001
4.04 p < 0.0001
4,04 p<0,0001
4.04 p < 0.0001
p<0,0001
4.1% (95% CI: 1.6% to
4,1% (95% CI: 1,6% do
4.11 Withdrawal period
Karencija
4.11 Withdrawal period(s)
Karencija
4.2 % sodium bicarbonate
4,2% natrijevim bikarbonatom
4.2 (3/71b)
19% (5/26)
4.2 ml solvent Plunger rod Vial adapter
Klip štrcaljke Nastavak za bočicu
4.25 mg/kg bodyweight/day
4,25 mg mg /kg tjelesne mase/dan
4.3 ml containing 2.15 mg fentanyl ensuring the delivery of 30 doses of 50 micrograms
4,3 ml sadrži 2,15 mg fentanila i osigurava unos 30 doza od 50 mikrograma.
4.3 ml containing 4.30 mg fentanyl ensuring the delivery of 30 doses of 100 micrograms
4,3 ml sadrži 4,30 mg fentanila i osigurava unos 30 doza od 100 mikrograma.
4.3 ml containing 8.60 mg fentanyl ensuring the delivery of 30 doses of 200 micrograms
4,3 ml sadrži 8,60 mg fentanila i osigurava unos 30 doza od 200 mikrograma.
4.3 ml once daily
3,5 ml jednom dnevno
4.3 ml once daily
4,3 ml jednom dnevno
4.3 ml twice daily
3,5 ml dvaput dnevno
4.3 ml twice daily
4,3 ml dva puta dnevno
4.3 ml twice daily
4,3 ml dvaput dnevno
4.3 Posology and method of administration
Doziranje i način primjene
4.3 Special warnings and precautions for use
Posebna upozorenja i mjere opreza pri uporabi
4.3 to 6.1
4,3 do 6,1
4.3 ± 1.5
(n=158) n/p 4,3 ± 1,5
4.3)
dio 4.3).
4.3).
Ctrough
4.3).
dio 4.3).
4.3).
tonavir
4.3. Immunogenicity data in preterm infants
Podaci o imunogenosti u prijevremeno rođene dojenčadi
4.3.)
dio 4.3).
4.31 (-7.62, 16.24)
Klinička remisija prema načelima Booleove algebre
4.4 and 5.2).
4.4 i 5.2).
4.4 m vs 2.2 m
4,4 m vs 2,2 m
4.4 ml for 3.5 mg dose
4,4 ml za dozu od 3,5 mg
4.4 months; HR = 0.670; p = 0.1208. A statistically significant improvement in OS was seen in the olaratumab plus doxorubicin arm in comparison to treatment with doxorubicin alone in the overall population.
U cjelokupnoj je populaciji primijećeno statistički značajno poboljšanje OS-a u skupini liječenoj olaratumabom plus doksorubicinom u odnosu na liječenje samo doksorubicinom.
4.4 µg of polysaccharide for serotype 6B
4,4 µg polisaharida za serotip 6B
4.4)
dio 4.4)
4.4).
Ciklosporin
4.4.
posljedica
4.4. Special warnings for each target species
Posebna upozorenja za svaku od ciljnih vrsta životinja
4.5 log10 copies/mL (range: 1.3-7.0) and 23% had baseline viral loads > 100,000 copies/mL.
4,5 log10 kopija/ml (raspon: 1,3-7,0), a 23% imalo je početno virusno opterećenje > 100 000 kopija/ml.
4.5 mg” on the body.
„RIV 4,5 mg“ na tijelu.
4.5 ml (ethanol 96% and water for injections).
4,5 ml (96%-tni etanol i voda za injekcije).
4.5 ml once daily
4,5 ml jednom dnevno
4.5 ml twice daily
4,5 ml dva puta dnevno
4.5 ml twice daily
4,5 ml dva puta na dan
4.5 ml twice daily
4,5 ml dvaput dnevno
4.5 vs.
4,5 naspram 3,7
4.5% (0 h 35 min)
4,5% (0 h 35 min)
4.5% (95% CI: -1.1%, 10.0%)
4,5% (95% CI: -1,1%; 10,0%)
4.5, Immunosuppressants, 4.8, and 5.1.
, Imunosupresivi, 4.8 i 5.1.
4.5. Interaction with other medicinal products and other forms of interaction
Interakcija s drugim lijekovima i ostali oblici interakcije
4.6 (2.8, NR)
4,6 (2,8; ND)
4.6 mg/24 h transdermal patch
4,6 mg/24 h transdermalni flaster
4.6 mg/24 h transdermal patch rivastigmine
4,6 mg/24 h transdermalni flaster rivastigmin
4.6 mg/24 h transdermal patch Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni flaster Rivastigmin 3M Health Care Ltd.
4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni flaster) ili 3,5 cm s 2,6 cm (Rivastigmin 3M Health Care Ltd.
4.6 mg/24 h transdermal patch) or “R10” (Rivastigmine 3M Health Care Ltd.
4,6 mg/24 h transdermalni flaster) ili „R10“ (Rivastigmin 3M Health Care Ltd.
4.6 mg/24 h.
4,6 mg/24 h.
4.6 mg/24h
Transdermalni
4.7**
MHS
4.8 log10 copies/ml
4,8 log10 kopija/ml
4.8 ml once daily
4,8 ml jednom dnevno
4.8 ml twice daily
4,8 ml dva puta dnevno
4.8 ml twice daily
4,8 ml dvaput dnevno
4.8. Undesirable effects
Nuspojave
4.9 Amounts to be administered and administration route
Doziranje i način primjene
4.9 Overdose
Antikolinergičko djelovanje
4.9 Overdose
Predoziranje
4.9% (95% CI =
4,9% (95% CI =
4.9% p=0.137 (-1.6, 11.3)
4,9% p=0,137 (-1,6; 11,3)
4.93 (41.66)
Fibrinogen
4.Put the tablet on the tongue as soon as it is removed from the packaging.
Stavite tabletu na jezik čim ju izvadite iz pakiranja.
40 % (0.4 IU/mL)
40% (0,4 IU/ml)
40 % of patients with bone marrow involvement responded compared to 59 % of patients with no bone marrow involvement (p=0.0186).
Odgovor je bio prisutan u 40% bolesnika sa zahvaćenošću koštane srži, u odnosu na 59% bolesnika u kojih nije bila zahvaćena koštana srž (p = 0,0186).
40 000 IU/1 ml
40000 IU/1 ml
40 20%; P < .0001
40 20%; P < 0,0001
40 boulevard de Champaret 38300 Bourgoin Jallieu France
40 boulevard de Champaret 38300 Bourgoin Jallieu Francuska
40 Boulevard de Champaret 38300 Bourgoin Jallieu, France
40 Boulevard de Champaret 38300 Bourgoin Jallieu, Francuska
40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANCE
40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANCUSKA
40 Boulevard de Champaret FR-38300 Bourgoin Jallieu France
40 Boulevard de Champaret FR-38300 Bourgoin Jallieu Francuska
40 capsules
40 kapsula
40 doses (20 ml).
40 doza (20 ml).
40 g sachet: do not store above 25 °C. 160 g sachet: do not store above 25 °C. 400 g sachet: do not store above 25 °C.
Vrećica 40 g: ne čuvati pri temperaturi iznad 25 °C. Vrećica 160 g: ne čuvati pri temperaturi iznad 25 °C. Vrećica od 400 g: ne čuvati pri temperaturi iznad 25 °C.
40 g sachet: do not store above 25 ºC.
Vrećica od 40 g: nemojte čuvati pri temperaturi iznad 25 C.
40 IU of FVIII per kg body weight at intervals of 2 to 3 days.
40 IU FVIII po kg tjelesne težine u intervalima od 2 do 3 dana.
40 IU/ml of insulin human
40 IU/ml ljudskog inzulina
40 kg) (see section 4.2).
od 40 kg) (vidjeti dio 4.2).
40 mcg/0.3 ml
40 mcg/0,3 ml
40 mg eow
40 mg svaki drugi tjedan
40 mg every other week.
40 mg svaki drugi tjedan.
40 mg Humira every other week
40 mg Humira svaki drugi tjedan
40 mg Humira every week
40 mg Humira svaki tjedan
40 mg once daily
150 mg dva puta
40 mg once daily
40 mg jedanput dnevno
40 mg single dose
40 mg jednokratna doza
40 mg single dose taken 12 hours before rilpivirine
jedna doza od 40 mg uzeta 12 sati prije rilpivirina
40 mg single dose taken 2 hours before rilpivirine
jedna doza od 40 mg uzeta 2 sata prije rilpivirina
40 mg single dose taken 4 hours after rilpivirine
jedna doza od 40 mg uzeta 4 sata nakon rilpivirina
40 mg subcutaneously once daily
40 mg supkutano jedanput na dan
40 mg tablets are white, oval, biconvex, with a break line and logo T on one side.
Tablete od 40 mg su bijele, ovalne, bikonveksne s razdjelnom linijom s oznakom T na jednoj strani.
40 mg tablets: Robenacoxib 40 mg
40 mg tablete: robenakoksib 40 mg
40 mg/12.5 mg tablets: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 15 mm x 7 mm.
40 mg/12,5 mg tablete: dvoslojna, bikonveksna, ovalna tableta, bijela do gotovo bijela ili ružičasto- bijela na jednoj strani te ružičasto mramorirana na suprotnoj strani, veličine 15 mm x 7 mm.
40 mg/kg/day
40 mg/kg/dan
40 mg/ml of tildipirosin
40 mg/ml Tildipirosina
40 mg/ml of tildipirosin
40 mg/ml Tildiprosin
40 mg/ml of tildipirosin
40 mg/ml Tildiprosina
40 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al+)
40 mikrograma Adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,50 miligrama Al+)
40 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 40 mikrograma
40 mL concentrate in a 50 mL vial (clear Type I glass) with stopper (butyl rubber).
40 ml koncentrata u bočici od 50 ml (bezbojno staklo tipa I) sa čepom (butilna guma).
40 ml HDPE-wide-necked bottle, with screwcap with integrated desiccant container(white silica gel), containing either 15, 30, 60, 90 or 100 film-coated tablets per container.
HDPE boca širokog grla volumena 40 ml s navojnim zatvaračem s ugrađenim spremnikom za sredstvo za sušenje (bijeli silika gel) koja sadrži 15, 30, 60, 90 ili 100 filmom obloženih tableta po spremniku.
40 ml HDPE-wide-necked bottle, with screwcap with integrated desiccant container(white silica gel), containing either 30, 60, 90 or 100 film-coated tablets per container.
HDPE boca širokog grla volumena 40 ml s navojnim zatvaračem s ugrađenim spremnikom za sredstvo za sušenje (bijeli silika gel) koja sadrži 30, 60, 90 ili 100 filmom obloženih tableta po spremniku.
40 mL of water for injections (WFI) should be added using a sterile syringe to reconstitute each vial to provide a 10 mg/mL solution per vial.
Sterilnom štrcaljkom potrebno je dodati 40 ml vode za injekcije za rekonstituciju svake bočice kako bi se dobilo 10 mg/ml otopine po bočici.
40 ml plastic bottle
Plastična bočica od 40 ml
40 ml vial
40 ml bočica
40 pipettes
40 pipeta
40 tablets
40 tableta
40 to 50 kg
40 do 50 kg
40 tubes
40 tuba
40 x 1 tablet (unit dose)
40 x 1 tableta (jedinična doza)
40 yrs
40 godina
40 µg/dose
40 µg/doza
40 – 50 microgram/24 h).
40 – 50 mikrograma/24 h).
40,000 IU/ml:
40 000 IU/ml:
40-49 3.3 mg* zoledronic acid
40-49 3,3 mg* zoledronatne kiseline
40.1 - 60
40,1 do 60
40.1 kg to 60 kg
40,1 kg do 60 kg
40.2 to 42.0
40,2 do 42,0
40.9%
(p=0,006
400 (10 cartridges x 40) tablets
400 (10 ulošci x 40) tableta
400 (2 x 200) vaccinal baits
400 (2 x 200) cjepnih mamaca
400 g sachet – 2 years.
vrećica od 40 g - 3 godine. vrećica od 400 g - 2 godine
400 g sachet – 2 years.
vrećica od 40 g - 3 godine. vrećica od 400 g - 2 godine.
400 g sachet: do not store above 25 °C.
Vrećica od 400 g: nemojte čuvati pri temperaturi iznad 25 °C
400 g sachet: do not store above 25 ºC.
Vrećica od 400 g: nemojte čuvati pri temperaturi iznad 25°C.
400 GBq (at ART) The volume depends on the quantity of medicines combined with Lumark required for administration by the nuclear medicine doctor.
Volumen ovisi o količini lijekova koji se kombiniraju s Lumarkom, koje treba primijeniti liječnik nuklearne medicine.
400 IU vitamin E, approximately 200 mg linoleic acid, 110 mg eicosapentaenoic acid (EPA), 210 mg alpha linolenic acid (ALA) and 80 mg docosahexaenoic acid (DHA) per day).
400 IU vitamina E, približno 200 mg linolne kiseline, 110 mg eikosapentaenoične kiseline (EPA), 210 mg alfa linolenske kiseline (ALA) i 80 mg dokosaheksaenoične kiseline (DHA) na dan);
400 IU/ml after reconstitution).
400 IU/ml nakon pripreme).
400 mcg EFFENTORA
400 mikrograma EFFENTORA
400 mg (0,2,4 weeks) with MTX
400 mg (tjedan 0,2,4) s MTX-om
400 mg (10 ml) every 12 hours for the first 24 hours
400 mg (10 ml) svakih 12 sati tijekom prva 24 sata
400 mg (20 ml) once daily
400 mg (20 ml) jedanput na dan
400 mg once
60 mg
400 mg once daily
300 mg jedanput na dan
400 mg once daily
400 mg jedanput
400 mg once daily
400 mg jedanput dnevno
400 mg once daily n=283 (%)
400 mg jedanput na dan n=283 (%)
400 mg powder for concentrate
400 mg prašak za koncentrat
400 mg single dose (saquinavir/ritonavir 1600/100 mg qd)
Didanozin pojedinačna doza od 400 mg (sakvinavir/ritonavir
400 mg tablet
tableta 400 mg
400 mg three times daily)
Victrelis 400 mg triput na dan )
400 mg to be taken as 1 capsule once a day,
400 mg se uzima kao 1 kapsula jednom na dan.
400 mg to be taken as 1 tablet once a day,
400 mg se uzima kao 1 tableta jednom na dan.
400 mg to be taken as 4 capsules once a day.
400 mg se uzima kao 4 kapsule jednom na dan.
400 mg to be taken as 4 tablets of 100 mg or 1 tablet of 400 mg once a day
400 mg se uzima kao 4 tablete od 100 mg ili 1 tableta od 400 mg jednomna dan.
400 mg to be taken as 4 tablets once a day,
400 mg se uzima kao 4 tablete jednom na dan,
400 mg to be taken as 8 capsules once a day.
400 mg se uzima kao 8 kapsula jednom na dan.
400 mg to be taken as one tablet once a day,
400 mg se uzima kao jedna tableta jednom na dan,
400 mg twice
400 mg
400 mg twice a day
400 mg dva puta na dan
400 mg twice daily
300 mg jednom dnevno
400 mg twice daily
400 mg dva puta
400 mg twice daily
400 mg dva puta dnevno
400 mg twice daily
400 mg dva puta na dan
400 mg twice daily
400 mg dvaput na dan (N=281)
400 mg twice daily (N = 281)
dvaput na dan
400 mg twice daily + OBT (N = 462)
400 mg dvaput na dan + OBT (N=462)
400 mg twice daily in patients with chronic or accelerated phase CML with resistance or intolerance to prior therapy.
400 mg dva puta na dan u bolesnika u kroničnoj ili ubrzanoj fazi KML-a s rezistencijom ili intolerancijom na prethodno liječenje.
400 mg twice daily n=281 (%)
400 mg dva puta na dan n=281 (%)
400 mg vial
Bočica od 400 mg
400 mg vial has a shelf life of 2 years.
Bočica sa 400 mg ima rok valjanosti 2 godine.
400 mg VIAL LABEL
NALJEPNICA NA BOČICI OD 400 mg
400 mg/100 mg twice daily
400 mg/100 mg
400 mg/m2
400 mg/m2, nakon kojeg
400 mg/m2 intravenous
intravenski bolus
400 mg/m2 intravenous bolus, followed by
intravenski bolus 400 mg/m2, nakon kojeg slijedi 600 mg/
400 micrograms fentanyl (as citrate)
400 mikrograma fentanila (u obliku fentanilcitrata)
400 ml polyethylene or multilayer plastic bags of solvent.
400 ml polietilen ili višeslojne plastične vrećice otapala.
400 mL white HDPE bottle containing 250 capsules with one 2-in-1 desiccant cylinder and two oxygen absorber cylinders, with a child resistant polypropylene closure.
Bijela bocaod polietilena visoke gustoće (HDPE) volumena 400 mL koja sadrži 250 kapsula s jednim 2u1 cilindričnim spremnikom sa sredstvom za sušenje i dvacilindričnim spremnikaza apsorpciju kisika, sa zatvaračem od polipropilena sigurnim za djecu.
400 pigs with an average bodyweight of 50 kg).
400 svinja prosječne mase 50 kg).
400 q12h
12h
400 q8h
400 svakih 8h
400 Shire Way, Lexington, Massachusetts 02421 USA
400 Shire Way, Lexington, Massachusetts 02421 SAD
400 µg / spray
400 μg / sprej
400/100 mg BID
Lopinavir/ritonavir
400/100 mg QD
Atazanavir/r 300/100mg:
400/100 mg twice daily
400/100 mg dva puta
400/100 mg twice daily
400/100 mg dva puta dnevno
400/100 mg twice daily
400/100 mg dva puta na
400/100 mg twice daily
50 mg jedanput dnevno +
400/100 mg twice daily).
400/100 mg dvaput na dan).
400/100 mg twice daily1
(0,92-1,05)
4000 (5 x 20 cartridges x 40) tablets (multipack)
4000 (5 x 20 ulošci x 40) tableta (višestruko pakiranje)
4000 IU/0.4 ml
3000 IU/0,3 ml
4000 IU/0.5 ml
Eporatio
40000 IU/1 ml
30000 IU/0,75 ml
40000 IU/1.0 ml
30000 IU/0,75 ml
40000 IU/1.0 ml
40000 IU/1 ml
402 mg fipronil,
fipronil 402 mg, (S)-metopren 361,8 mg, amitraz
4020 Linz Austria
A-4020 Linz Austrija
4042 Debrecen Hungary
4042 Debrecen Mađarska
4042 Debrecen,
4042 Debrecen, Mađarska
4042 Debrecen, Hungary
4042 Debrecen, Mađarska
40549 Düsseldorf Germany
40549 Düsseldorf Njemačka
4056 Basel Switzerland
4056 Basel Švicarska
406 patients who received docetaxel in combination with cisplatin.
406 bolesnika koji su primali docetaksel u kombinaciji s cisplatinom,
40–49 3.3 mg* zoledronic acid
3,3 mg* zoledronatne kiseline
40–49 3.3 mg* zoledronic acid
40 – 49 3,3 mg* zoledronatne kiseline
41 (13)b
45 (41)
41 Chalton Street London, NW1 1JD United Kingdom
41 Chalton Street London, NW1 1JD
41 children with SMEI were included in a randomised, placebo-controlled, add-on trial.
41 dijete sa SMEI je bilo uključeno u randomiziranu placebo kontroliranu studiju tipa add-on.
41 hours in cancer patients.
41 sat u bolesnika s rakom.
41% received bisphosphonates.
41% primalo je bisfosfonate.
41.7 (32.6 to 51.6)
41,7 (32,6 do 51,6)
410 units*
410 jedinica
410 units*.
410 jedinica*.
412 patients were treated for up to 12 weeks and 333 patients were treated for up to 24 weeks at the 300 mg dose.
Od njih, 412 bolesnika bilo je liječeno do 12 tjedana, a 333 bolesnika bilo je liječeno do 24 tjedna dozom od 300 mg.
42 (3 x 14) vials + 42 (3 x 14) pre-filled syringes (luer lock) (multipack)
42 (3 x 14) bočice + 42 (3 x 14) napunjene štrcaljke (luer zatvarač) (višestruko pakovanje)
42 (3 x 14) vials + 45 (3 x 15) pre-filled syringes (luer lock) (multipack)
42 (3 x 14) bočice + 45 (3 x 15) napunjenih štrcaljki (luer zatvarač) (višestruko pakovanje)
42 ampoules
42 ampule
42 AMPOULES WITH 1 ML
42 AMPULE S 1 ML
42 ampoules.
42 ampule.
42 film-coated tablets 84 film-coated tablets 90 film-coated tablets 294 film-coated tablets
42 filmom obložene tablete 84 filmom obloženih tableta 90 filmom obloženih tableta 294 filmom obloženih tableta
42 film-coated tablets of 15 mg rivaroxaban and 7 film-coated tablets of 20 mg rivaroxaban in a wallet.
42 filmom obložene tablete od 15 mg rivaroksabana i 7 filmom obloženih tableta od 20 mg rivaroksabana u ovitku oblika novčanika.
42 film-coated tablets Xarelto 15 mg and 7 film-coated tablets Xarelto 20 mg.
42 filmom obložene tablete lijeka Xarelto 15 mg i 7 filmom obloženih tableta lijeka Xarelto 20 mg.
42 hard capsules
42 kapsule
42 months after completion of the full vaccination course, 100% and 99.4% of initially seronegative women remained seropositive for anti-HPV-16 and anti-HPV-18 antibodies, respectively.
42 mjeseca nakon završetka potpunog rasporeda cijepljenja, 100% odnosno 99,4% početno seronegativnih žena ostalo je seropozitivno za anti-HPV-16 odnosno anti-HPV-18 protutijela.
42 pipettes
42 pipete
42 sachets
42 vrećice
42 single-use vials
42 bočice za jednokratnu upotrebu
42 tablets
42 tableta
42 tablets
42 tablete
42 tablets: two transparent calendar blisters of 21 tablets each.
42 tablete: dva prozirna kalendarska blistera, svaki s 21 tabletom.
42 x 1 hard capsules: blister
42 x 1 tvrda kapsula: blister
42% of patients did not receive prior docetaxel because they were deemed ineligible or refused to receive docetaxel.
42% bolesnika nije prethodno primalo docetaksel, jer ih se je smatralo nepodobnima ili su odbili primati docetaksel.
42.0 micrograms
42,0 mikrograma
42.0% (29/69)
4,2 (3/71b)
42.1 to 43.9
42,1 do 43,9
42.3
primjene
425 medical patients who are at risk for thromboembolic complications treated up to 14 days
u 425 nekirurških bolesnika s rizikom od tromboembolijskih komplikacija liječenih tijekom
428 patients with active rheumatoid arthritis despite treatment with methotrexate.
102. tjedna u 428 bolesnika koji su imali aktivni reumatoidni artritis usprkos liječenju metotreksatom.
43 (67.2%) were ≥ 2 years to 11 years old, 15 (23.4%) were between 1 and 2 years old, and 6 (9.4%) were between 3 months and 1 year old.
43 (67,2%) ih je bilo  2 do 11 godina starosti, 15 (23,4%) ih je bilo između 1 i 2 godine starosti te njih 6 (9,4%) bilo je staro između 3 mjeseca i 1 godine.
43.1 mo (35.3, 48.3)
43,1 mjesec (35,3; 48,3)
43.1 mo (35.3, 48.3)
43,1 mjeseci (35,3, 48,3)
43.1 mo(35.3, 48.3)
43,1 mjesec (35,3; 48,3)
43.3% vs 29.2%
43,3% vs 29,2
43056 San Polo di Torrile, Parma Italy
43056 San Polo di Torrile, Parma Italija
43122 Parma Italy
43122 Parma Italija
43122 Parma, Italy
43122 Parma, Italija
43122 PARMA-ITALY
43122 PARMA-ITALIJA
433±286 ng • h/ml.
433 ± 286 ng • h/ml.
436 mg dinotefuran,
436 mg dinotefurana,
437.5 mg (5.5 ml) twice daily
437,5 mg (5,5 ml) dva puta na dan
44 mg dinotefuran,
44 mg dinotefurana,
44 mg dinotefuran,
44 mg dinotefuranaa,
44 micrograms (12 million IU)/0.5 mL
44 mikrograma (12 milijuna IU)/0,5 ml
44 micrograms tiw
44 mikrograma tri puta tjedno
44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
U 44 bolesnika sa shizofrenijom starijih od 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
U 44 bolesnika sa shizofrenijom, starijih od 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
44 patients with schizophrenia  65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.